<DOC>
	<DOCNO>NCT00764465</DOCNO>
	<brief_summary>To date , study investigate whether drug interaction protease inhibitor fosamprenavir entry inhibitor maraviroc . COL112237 randomize , open-label , 6-arm , 3-period , drug interaction study ass steady-state plasma amprenavir ( APV ) maraviroc ( MVC ) pharmacokinetics 48 healthy , HIV-negative adult administration 7-day regimen MVC 300mg BID alone 14-day regimen unboosted fosamprenavir ( FPV ) 1400mg twice daily ( BID ) , FPV 700mg/RTV 100mg BID , FPV 1400mg/ritonavir ( RTV ) 100mg daily ( QD ) without concurrent MVC 300mg BID . Blood sample drug concentration measurement collect 12 hour end dose period . Subjects undergo physical examination , complete blood count ( CBC ) differential , HIV test , hepatitis B/C test , liver function test , renal function analysis , lipid panel screening , test , except HIV hepatitis B/C , repeat follow-up post-study . Adverse event adherence ( pill count medication diary ) assess investigator/study personnel end dose period .</brief_summary>
	<brief_title>An Interaction Study Assess Drug Levels Healthy Adult Subjects</brief_title>
	<detailed_description>This randomize , open-label , six-arm , three-period drug interaction study recruit 48 healthy volunteer obtain minimum 36 evaluable subject single study center U.S . The study screen visit , 3 treatment visit PK sample follow-up visit . The screen visit conduct within 30 day prior receive first dose . Subjects randomize 1 6 treatment group show : Cohort Size Period 1 Days 1 7 Period 2 Days 1-14 Period 3 Days 1-14 A 8 MVC 300mg BID ; FPV 1400mg BID ; FPV 1400mg BID &amp; MVC 300mg BID B 8 MVC 300mg BID ; FPV 1400mg BID &amp; MVC 300mg BID ; FPV 1400mg BID C 8 MVC 300mg BID ; FPV 700mg BID &amp; RTV 100mg BID ; FPV 700mg BID &amp; RTV 100mg BID &amp; MVC 300mg BID D 8 MVC 300mg BID ; FPV 700mg BID &amp; RTV 100mg BID &amp; MVC 300mg BID ; FPV 700mg BID &amp; RTV 100mg BID E 8 MVC 300mg BID ; FPV 1400mg QD &amp; RTV 100mg QD ; FPV 1400mg QD &amp; RTV 100mg QD &amp; MVC 300mg BID F 8 MVC 300mg BID ; FPV 1400mg QD &amp; RTV 100mg QD &amp; MVC 300mg BID ; FPV 1400mg QD &amp; RTV 100mg QD Study subject enter clinic morning prior dose remain center 12 hour follow dose . Fourteen 21 day follow completion third dosing period , study subject return clinic follow-up assessment . The total duration study approximately 86 day screen follow . Blood sample drug concentration measurement amprenavir ( APV ) maraviroc ( MVC ) concentration collect 12 hour end dose period ( 0 [ baseline ] , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 hour post-dose ) . Subjects undergo physical examination , CBC differential , HIV test , hepatitis B/C test , liver function test , renal function analysis , lipid panel screening , test except HIV hepatitis B/C repeat follow-up post-study . Adverse event adherence ( pill count medication diary ) assess investigator/study personnel end dose period . Evaluable patient require adhere least 95 % study drug dos . Plasma APV MVC concentration analyze use validate high-performance liquid chromatography method tandem mass spectrometric detection ( HPLC/MS/MS ) . Plasma APV MVC pharmacokinetic parameter measure include maximum concentration ( Cmax ) , time maximum concentration ( Tmax ) , minimum concentration ( Cmin ) , area concentration-time curve ( AUC ) . All parameter , except Tmax , log-transformed statistical analysis . Analysis variance , consider treatment fix effect subject random effect perform use Statistical Analysis Software ( SAS ) , assume treatment ratio steady-state APV PK parameter 1.0 , 90 % confidence interval within range 0.81-1.24 .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy subject clinically significant abnormality identify physician evaluation medical history , physical examination , clinical laboratory test vital sign . 18 64 year , A female subject eligible participate neither pregnant lactating , fall one follow category : nonchildbearing potential include female document ( medical report verification ) hysterectomy bilateral oophorectomy , postmenopausal female define amenorrheic great 1 year estradiol follicle stimulate hormone ( FSH ) level consistent menopause . childbearing potential negative serum pregnancy test screen agree use one follow method contraception screen least two week prior first dose ( whichever earlier ) followup visit ( contraception method must use consistently correctly , i.e. , accordance product label instruction physician ) . Agreement complete abstinence intercourse Double barrier contraception ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) Any intrauterine device ( IUD ) publish data show expected failure rate le 1 % per year ( IUDs meet criterion ) Any method publish data show low expected failure rate method le 1 % per year . Adequate renal function ( calculated creatinine clearance via Cockcroft Gault method ( CrCl ) &gt; 50 mL/min ) ; Adequate hepatic function ( total bilirubin &lt; 2.5mg/dL ; hepatic transaminase &lt; 5x normal ) ; Adequate hematologic function ( absolute neutrophil count [ ANC ] &gt; 750 neutrophils/mm^3 ; platelet &gt; 50,000/mm^3 ; hematocrit &gt; 25 % ) ; Nonsmoker , define use nicotinecontaining product within past 6 month . Willingness ability adhere treatment followup procedure ; The ability understand sign write informed consent form . Body weight &gt; =50 kg male &gt; or=45 kg female body mass index ( BMI ) range 19 30 kg/m^2 ( BMI = weight [ kg ] / ( height [ ] ) ^2 ) . â€¢ Have active infection require parenteral antibiotic hospitalization within 2 week prior enrollment ; A history document gastrointestinal disease impact drug absorption ; Have significant document sulfa allergy ( e.g. , StevensJohnson Syndrome ) history sensitivity study medication , component thereof ; HIV , Hepatitis B C positive Cigarette/cigar/pipe smoker ; History alcohol/drug abuse dependence within 12 month study , history alcohol consumption past six month exceed 7 units/week woman 14 units/week men ( 1 unit = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Use prescription nonprescription drug ( include aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) , vitamin , herbal dietary supplement within 7 day ( 14 day drug potential enzyme inducer , St. John 's Wort ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion investigator medication interfere study procedure compromise subject safety . Subjects donate plasma within 7 day prior screen visit participation study would result donation blood excess 500 mL blood within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Pharmacokinetics study</keyword>
	<keyword>Pharmacokinetics medication</keyword>
</DOC>